Limits...
Berberine attenuates experimental autoimmune encephalomyelitis in C57 BL/6 mice.

Ma X, Jiang Y, Wu A, Chen X, Pi R, Liu M, Liu Y - PLoS ONE (2010)

Bottom Line: Berberine, an isoquinoline derivative alkaloid, has a wide range of pharmacological properties and is considered to have anti-inflammatory and neuroprotective effects.These findings suggest that berberine is effective to attenuate the clinical severity of EAE in C57 BL/6 mice by reducing the permeability of BBB, decreasing the expression and activity of MMP-9, and decreasing the inflammatory infiltration.We think that berberine might be a potential therapeutic agent for MS.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.

ABSTRACT

Background: Berberine, an isoquinoline derivative alkaloid, has a wide range of pharmacological properties and is considered to have anti-inflammatory and neuroprotective effects. However, there are no reports about the effects and mechanisms of berberine in experimental autoimmune encephalomyelitis (EAE), an established model of multiple sclerosis (MS).

Methodology/principal findings: Female C57 BL/6 mice immunized with myelin oligodendrocyte glycoprotein 35-55 amino acid peptide were treated with berberine at the day of disease onset and medication was administered daily until mice were sacrificed. Blood-brain barrier (BBB) permeability and the alteration of matrix metalloproteinase-2 (MMP-2, 72 kDa) and matrix metalloproteinase-9 (MMP-9, 92 kDa) in the brain and cerebrospinal fluid (CSF) of EAE mice were detected by quantitative measurement for Evan's blue (EB) content, Western blot and gelatin zymography respectively. The results showed that berberine attenuated clinical and pathological parameters of EAE, reduced the permeability of BBB, inhibited the activity and expression of MMP-9 but not MMP-2 in the CSF and brain of EAE mice.

Conclusions/significance: These findings suggest that berberine is effective to attenuate the clinical severity of EAE in C57 BL/6 mice by reducing the permeability of BBB, decreasing the expression and activity of MMP-9, and decreasing the inflammatory infiltration. We think that berberine might be a potential therapeutic agent for MS.

Show MeSH

Related in: MedlinePlus

Effects of berberine on the expression of MMP-2 and MMP-9 in the brain of different treated mice.The brains from different treated mice were harvested for Western blot at day 20 p.i.. Each group had seven animals. Values represent the mean± S.E.M., **P<0.01 vs control mice, ##P<0.01, vs PBS-treated EAE mice.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2957444&req=5

pone-0013489-g005: Effects of berberine on the expression of MMP-2 and MMP-9 in the brain of different treated mice.The brains from different treated mice were harvested for Western blot at day 20 p.i.. Each group had seven animals. Values represent the mean± S.E.M., **P<0.01 vs control mice, ##P<0.01, vs PBS-treated EAE mice.

Mentions: The brains of control mice, PBS- and berebrine-treated EAE mice were obtained at day 20 p.i. (n = 7). The expression of MMP-2 and MMP-9 in the brains of different treated mice were detected by Western blot. The bands were quantified with the Quantity one image analysis software. A significant increase of MMP-2 and MMP-9 expression in the brain of PBS-treated EAE mice was recorded compared with that of the control mice (P<0.01). The increase of MMP-9 was significantly attenuated in animals treated with berberine when compared with PBS (P<0.01). However, the expression of MMP-2 in the brain of PBS- and berberine-treated EAE mice didn't show significant difference. (P>0.05, Fig. 5).


Berberine attenuates experimental autoimmune encephalomyelitis in C57 BL/6 mice.

Ma X, Jiang Y, Wu A, Chen X, Pi R, Liu M, Liu Y - PLoS ONE (2010)

Effects of berberine on the expression of MMP-2 and MMP-9 in the brain of different treated mice.The brains from different treated mice were harvested for Western blot at day 20 p.i.. Each group had seven animals. Values represent the mean± S.E.M., **P<0.01 vs control mice, ##P<0.01, vs PBS-treated EAE mice.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2957444&req=5

pone-0013489-g005: Effects of berberine on the expression of MMP-2 and MMP-9 in the brain of different treated mice.The brains from different treated mice were harvested for Western blot at day 20 p.i.. Each group had seven animals. Values represent the mean± S.E.M., **P<0.01 vs control mice, ##P<0.01, vs PBS-treated EAE mice.
Mentions: The brains of control mice, PBS- and berebrine-treated EAE mice were obtained at day 20 p.i. (n = 7). The expression of MMP-2 and MMP-9 in the brains of different treated mice were detected by Western blot. The bands were quantified with the Quantity one image analysis software. A significant increase of MMP-2 and MMP-9 expression in the brain of PBS-treated EAE mice was recorded compared with that of the control mice (P<0.01). The increase of MMP-9 was significantly attenuated in animals treated with berberine when compared with PBS (P<0.01). However, the expression of MMP-2 in the brain of PBS- and berberine-treated EAE mice didn't show significant difference. (P>0.05, Fig. 5).

Bottom Line: Berberine, an isoquinoline derivative alkaloid, has a wide range of pharmacological properties and is considered to have anti-inflammatory and neuroprotective effects.These findings suggest that berberine is effective to attenuate the clinical severity of EAE in C57 BL/6 mice by reducing the permeability of BBB, decreasing the expression and activity of MMP-9, and decreasing the inflammatory infiltration.We think that berberine might be a potential therapeutic agent for MS.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.

ABSTRACT

Background: Berberine, an isoquinoline derivative alkaloid, has a wide range of pharmacological properties and is considered to have anti-inflammatory and neuroprotective effects. However, there are no reports about the effects and mechanisms of berberine in experimental autoimmune encephalomyelitis (EAE), an established model of multiple sclerosis (MS).

Methodology/principal findings: Female C57 BL/6 mice immunized with myelin oligodendrocyte glycoprotein 35-55 amino acid peptide were treated with berberine at the day of disease onset and medication was administered daily until mice were sacrificed. Blood-brain barrier (BBB) permeability and the alteration of matrix metalloproteinase-2 (MMP-2, 72 kDa) and matrix metalloproteinase-9 (MMP-9, 92 kDa) in the brain and cerebrospinal fluid (CSF) of EAE mice were detected by quantitative measurement for Evan's blue (EB) content, Western blot and gelatin zymography respectively. The results showed that berberine attenuated clinical and pathological parameters of EAE, reduced the permeability of BBB, inhibited the activity and expression of MMP-9 but not MMP-2 in the CSF and brain of EAE mice.

Conclusions/significance: These findings suggest that berberine is effective to attenuate the clinical severity of EAE in C57 BL/6 mice by reducing the permeability of BBB, decreasing the expression and activity of MMP-9, and decreasing the inflammatory infiltration. We think that berberine might be a potential therapeutic agent for MS.

Show MeSH
Related in: MedlinePlus